BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 28923615)

  • 21. Steroid Withdrawal Using Everolimus in ABO-Incompatible Kidney Transplant Recipients With Post-Transplant Diabetes Mellitus.
    Nanmoku K; Shinzato T; Kubo T; Shimizu T; Kimura T; Yagisawa T
    Transplant Proc; 2018 May; 50(4):1050-1055. PubMed ID: 29631750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen-Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil.
    Traitanon O; Mathew JM; Shetty A; Bontha SV; Maluf DG; El Kassis Y; Park SH; Han J; Ansari MJ; Leventhal JR; Mas V; Gallon L
    PLoS One; 2019; 14(5):e0216300. PubMed ID: 31136582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
    Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
    Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
    Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
    Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effective and Safe Reduction of Conventional Immunosuppressants Using Everolimus in Maintenance Kidney Transplant Recipients.
    Nanmoku K; Kurosawa A; Kubo T; Shinzato T; Shimizu T; Kimura T; Yagisawa T
    Transplant Proc; 2017 Oct; 49(8):1724-1728. PubMed ID: 28923615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Mycophenolate Mofetil Dose Reduction on Allograft Outcomes in Kidney Transplant Recipients on Tacrolimus-Based Regimens: A Systematic Review.
    Su VCh; Greanya ED; Ensom MH
    Ann Pharmacother; 2011 Feb; 45(2):248-57. PubMed ID: 21304036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Everolimus with early withdrawal or reduced-dose calcineurin inhibitors improves renal function in liver transplant recipients: A systematic review and meta-analysis.
    Lin M; Mittal S; Sahebjam F; Rana A; Sood GK
    Clin Transplant; 2017 Feb; 31(2):. PubMed ID: 27862340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
    Jones-Hughes T; Snowsill T; Haasova M; Coelho H; Crathorne L; Cooper C; Mujica-Mota R; Peters J; Varley-Campbell J; Huxley N; Moore J; Allwood M; Lowe J; Hyde C; Hoyle M; Bond M; Anderson R
    Health Technol Assess; 2016 Aug; 20(62):1-594. PubMed ID: 27578428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of everolimus plus low-dose calcineurin inhibitor vs. mycophenolate mofetil plus standard-dose calcineurin inhibitor in renal transplant recipients: A systematic review and meta-analysis
.
    He L; Deng J; Yang B; Jiang W
    Clin Nephrol; 2018 May; 89(5):336-344. PubMed ID: 29292693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Everolimus in liver transplantation.
    Trotter JF; Lizardo-Sanchez L
    Curr Opin Organ Transplant; 2014 Dec; 19(6):578-82. PubMed ID: 25254569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunosuppressive therapy post-transplantation in children: what the clinician needs to know.
    Tönshoff B
    Expert Rev Clin Immunol; 2020 Feb; 16(2):139-154. PubMed ID: 31952458
    [No Abstract]   [Full Text] [Related]  

  • 33. Safety and Efficacy of Two Different Doses of Everolimus in Kidney Transplantation: a Systematic Review and Meta-Analysis.
    Arab-Zozani M; Mahdavi-Mazdeh M; Hasanpoor E; Ghoddoosi Nejad D; Sokhanvar M; Kakemam E
    Iran J Kidney Dis; 2016 Jan; 11(1):1-11. PubMed ID: 28174346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of everolimus in liver transplantation.
    Yee ML; Tan HH
    World J Hepatol; 2017 Aug; 9(23):990-1000. PubMed ID: 28878864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of steroid avoidance and novel protocols on growth in paediatric renal transplant patients.
    Grenda R
    Pediatr Nephrol; 2010 Apr; 25(4):747-52. PubMed ID: 19844746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of complications from use of conventional immunosuppressants: a critical review.
    Ponticelli C; Glassock RJ
    J Nephrol; 2019 Dec; 32(6):851-870. PubMed ID: 30927190
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.